EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis

Oncogene

Volumn 30, Issue 50, 2011, Pages 4941-4952

  Zhang, S ^a   Wang, X ^a   Osunkoya, A O ^a   Iqbal, S ^a   Wang, Y ^a   Chen, Z ^a,b   Muller S ^a   Josson, S ^c   Coleman, I M ^d   Nelson, P S ^d   Wang, Y A ^e   Wang, R ^c   Shin, D M ^a   Marshall, F F ^a   Kucuk, O ^a   Chung, L W K ^c   Zhau, H E ^c   Wu, D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e OCEAN NANOTECH LLC   (United States)

Author keywords

cytoskeleton; epithelial mesenchymal transition; EPLIN; lymph node metastasis; prostate cancer

Indexed keywords

ACTIN; ACTIN BINDING PROTEIN; BETA CATENIN; EPITHELIAL PROTEIN LOST IN NEOPLASM; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CELL JUNCTION; CHEMICAL ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ADHERENS JUNCTIONS; BETA CATENIN; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 83555173589     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.199     Document Type: Article

References (53)

1. Abe K, Takeichi M. (2008). EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proc Natl Acad Sci USA 105: 13-19.
2. Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS et al. (2009). Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate 69: 1-11.
3. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W et al. (2007). Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7: 64.
4. Chen S, Maul RS, Kim HR, Chang DD. (2000). Characterization of the human EPLIN (epithelial protein lost in neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. Gene 248: 69-76. (Pubitemid 30259202)
5. Chircop M, Oakes V, Graham ME, Ma MP, Smith CM, Robinson PJ et al. (2009). The actin-binding and bundling protein, EPLIN, is required for cytokinesis. Cell Cycle 8: 757-764.
6. Dong JT, Chen C. (2009). Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 66: 2691-2706.
7. Emadi Baygi M, Soheili ZS, Schmitz I, Sameie S, Schulz WA. (2010). Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol 26: 553-567.
8. Fidler IJ. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458. (Pubitemid 37328849)
9. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M et al. (2008). Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68: 2479-2488. (Pubitemid 351521824)
10. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L, Mansel RE. (2008). Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7: 71.
11. Katiyar SK. (2006). Matrix metalloproteinases in cancer metastasis: molecular targets for prostate cancer prevention by green tea polyphenols and grape seed proanthocyanidins. Endocr Metab Immune Disord Drug Targets 6: 17-24. (Pubitemid 43796710)
12. Keshamouni VG, Jagtap P, Michailidis G, Strahler JR, Kuick R, Reka AK et al. (2009). Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J Proteome Res 8: 35-47.
13. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A et al. (2006). Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 5: 1143-1154. (Pubitemid 43727792)
14. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A et al. (2007). Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6: 559-570. (Pubitemid 46340160)
15. Khwaja FW, Svoboda P, Reed M, Pohl J, Pyrzynska B, Van Meir EG. (2006). Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene 25: 7650-7661. (Pubitemid 44924478)
16. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T et al. (2009). Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26: 433-446.
17. Koreckij TD, Trauger RJ, Montgomery RB, Pitts TE, Coleman I, Nguyen H et al. (2009). HE3235 inhibits growth of castration-resistant prostate cancer. Neoplasia 11: 1216-1225.
18. Kwon M, MacLeod TJ, Zhang Y, Waisman DM. (2005). S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasmino-gen receptors. Front Biosci 10: 300-325. (Pubitemid 40543035)
19. Lang SH, Frame FM, Collins AT. (2009). Prostate cancer stem cells. J Pathol 217: 299-306.
20. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816. (Pubitemid 38121040)
21. Larriba MJ, Casado-Vela J, Pendas-Franco N, Pena R, Garcia de Herreros A, Berciano MT et al. (2010). Novel snail1 target proteins in human colon cancer identified by proteomic analysis. PLoS One 5: e10221.
22. Liu J, Uygur B, Zhang Z, Shao L, Romero D, Vary C et al. (2010). Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression. Prostate 70: 1768-1777.
23. Machesky LM, Tang HR. (2009). Actin-based protrusions: promoters or inhibitors of cancer invasion? Cancer Cell 16: 5-7.
24. Mathias RA, Simpson RJ. (2009). Towards understanding epithelial-mesenchymal transition: a proteomics perspective. Biochim Biophys Acta 1794: 1325-1331.
25. Maul RS, Chang DD. (1999). EPLIN, epithelial protein lost in neoplasm. Oncogene 18: 7838-7841. (Pubitemid 30052769)
26. Maul RS, Song Y, Amann KJ, Gerbin SC, Pollard TD, Chang DD. (2003). EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. J Cell Biol 160: 399-407. (Pubitemid 36182730)
27. McKeithen D, Graham T, Chung LW, Odero-Marah V. (2010). Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 70: 982-992.
28. O'Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. (2010). S100A10 regulates plasminogen-dependent macrophage invasion. Blood 116: 1136-1146.
29. Percipalle P, Raju CS, Fukuda N. (2009). Actin-associated hnRNP proteins as transacting factors in the control of mRNA transport and localization. RNA Biol 6: 171-174.
30. Pokutta S, Weis WI. (2007). Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu Rev Cell Dev Biol 23: 237-261.
31. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353. (Pubitemid 38529873)
32. Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR et al. (2003). Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res 63: 4786-4791. (Pubitemid 37022606)
33. Schmalhofer O, Brabletz S, Brabletz T. (2009). E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166.
34. Schneider R, Grosschedl R. (2007). Dynamics and interplay of nuclear architecture, genome organization, and gene expression. Genes Dev 21: 3027-3043. (Pubitemid 350223521)
35. Smith SC, Theodorescu D. (2009). Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9: 253-264.
36. Song Y, Maul RS, Gerbin CS, Chang DD. (2002). Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Mol Biol Cell 13: 1408-1416. (Pubitemid 34309632)
37. Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS et al. (2008). Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res 68: 9996-10003.
38. Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
39. Thiolloy S, Rinker-Schaeffer CW. (2010). Thinking outside the box: using metastasis suppressors as molecular tools. Semin Cancer Biol 21: 89-98.
40. Tusher VG, Tibshirani R, Chu G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121. (Pubitemid 32397092)
41. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA et al. (2005). Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406. (Pubitemid 41579834)
42. Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P et al. (2008). Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res 28: 327-334. (Pubitemid 351362921)
43. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487-1495.
44. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G et al. (2005). Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11: 8006-8014. (Pubitemid 41698741)
45. Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shen SS et al. (2007). Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 104: 12784-12789. (Pubitemid 47255232)
46. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O et al. (2007). cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26: 5070-5077. (Pubitemid 47206947)
47. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A et al. (2006). Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66: 1664-1673. (Pubitemid 44646357)
48. Yamazaki D, Kurisu S, Takenawa T. (2005). Regulation of cancer cell motility through actin reorganization. Cancer Sci 96: 379-386. (Pubitemid 41179738)
49. Yilmaz M, Christofori G. (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33.
50. Yilmaz M, Christofori G. (2010). Mechanisms of motility in metastasizing cells. Mol Cancer Res 8: 629-642.
51. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L et al. (2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799. (Pubitemid 41079896)
52. Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S et al. (2010). Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 9: 9.
53. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G et al. (2008). Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 25: 601-610.